198 related articles for article (PubMed ID: 24885236)
1. Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.
van Laar R; Flinchum R; Brown N; Ramsey J; Riccitelli S; Heuck C; Barlogie B; Shaughnessy JD
BMC Med Genomics; 2014 May; 7():25. PubMed ID: 24885236
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Broyl A; Hose D; Lokhorst H; de Knegt Y; Peeters J; Jauch A; Bertsch U; Buijs A; Stevens-Kroef M; Beverloo HB; Vellenga E; Zweegman S; Kersten MJ; van der Holt B; el Jarari L; Mulligan G; Goldschmidt H; van Duin M; Sonneveld P
Blood; 2010 Oct; 116(14):2543-53. PubMed ID: 20574050
[TBL] [Abstract][Full Text] [Related]
3. Insights from the gene expression profiling of multiple myeloma.
Claudio JO; Masih-Khan E; Stewart AK
Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling defines a high-risk entity of multiple myeloma.
Zhan FH; Barlogie B; John D S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
[TBL] [Abstract][Full Text] [Related]
5. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma.
Zamani-Ahmadmahmudi M; Nassiri SM; Soltaninezhad F
Br J Haematol; 2021 Jan; 192(2):310-321. PubMed ID: 32410217
[TBL] [Abstract][Full Text] [Related]
6. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
8. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Carrasco DR; Tonon G; Huang Y; Zhang Y; Sinha R; Feng B; Stewart JP; Zhan F; Khatry D; Protopopova M; Protopopov A; Sukhdeo K; Hanamura I; Stephens O; Barlogie B; Anderson KC; Chin L; Shaughnessy JD; Brennan C; Depinho RA
Cancer Cell; 2006 Apr; 9(4):313-25. PubMed ID: 16616336
[TBL] [Abstract][Full Text] [Related]
9. CD138
Shuai W; Li S
Blood; 2019 Sep; 134(11):906. PubMed ID: 31515228
[No Abstract] [Full Text] [Related]
10. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome.
Papadimitriou MA; Papanota AM; Adamopoulos PG; Pilala KM; Liacos CI; Malandrakis P; Mavrianou-Koutsoukou N; Patseas D; Eleutherakis-Papaiakovou E; Gavriatopoulou M; Kastritis E; Avgeris M; Dimopoulos MA; Terpos E; Scorilas A
Br J Cancer; 2022 Jan; 126(1):79-90. PubMed ID: 34718359
[TBL] [Abstract][Full Text] [Related]
11. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
Boyle EM; Rosenthal A; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Davies FE; Walker BA; van Rhee F; Morgan GJ
Br J Haematol; 2021 Oct; 195(2):283-286. PubMed ID: 34244996
[No Abstract] [Full Text] [Related]
12. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
13. The molecular classification of multiple myeloma.
Zhan F; Huang Y; Colla S; Stewart JP; Hanamura I; Gupta S; Epstein J; Yaccoby S; Sawyer J; Burington B; Anaissie E; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Walker R; Zangari M; Crowley J; Barlogie B; Shaughnessy JD
Blood; 2006 Sep; 108(6):2020-8. PubMed ID: 16728703
[TBL] [Abstract][Full Text] [Related]
14. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.
Johnson SK; Heuck CJ; Albino AP; Qu P; Zhang Q; Barlogie B; Shaughnessy JD
Int J Hematol; 2011 Oct; 94(4):321-333. PubMed ID: 22002477
[TBL] [Abstract][Full Text] [Related]
15. Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.
Bret C; Hose D; Reme T; Sprynski AC; Mahtouk K; Schved JF; Quittet P; Rossi JF; Goldschmidt H; Klein B
Br J Haematol; 2009 May; 145(3):350-68. PubMed ID: 19298595
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Nair B; Shaughnessy JD; Zhou Y; Astrid-Cartron M; Qu P; van Rhee F; Anaissie E; Alsayed Y; Waheed S; Hollmig K; Szymonifka J; Petty N; Hoering A; Barlogie B
Blood; 2009 Jun; 113(26):6572-5. PubMed ID: 19389881
[TBL] [Abstract][Full Text] [Related]
17. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
Dickens NJ; Walker BA; Leone PE; Johnson DC; Brito JL; Zeisig A; Jenner MW; Boyd KD; Gonzalez D; Gregory WM; Ross FM; Davies FE; Morgan GJ
Clin Cancer Res; 2010 Mar; 16(6):1856-64. PubMed ID: 20215539
[TBL] [Abstract][Full Text] [Related]
18. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout.
Jacak J; Schnidar H; Muresan L; Regl G; Frischauf A; Aberger F; Schütz GJ; Hesse J
J Biotechnol; 2013 Apr; 164(4):525-30. PubMed ID: 23416329
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and risk stratification in multiple myeloma.
van de Donk NW; Sonneveld P
Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
